MERMAID-2

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

Enquire

Trial overview

Topic

Carcinoma, non-small cell lung

Eligibility criteria

Early Stage Non-Small Cell Lung Cancer requiring surgery
No known mutations in the lung cancer
Completion of adjuvant chemotherapy, or no chemotherapy

Study details

This study requires tumour tissue and blood tests close to the date of the lung cancer surgery. This assessment determines the eligibility for the trial.

There is close follow up with blood tests after completion of intial chemotherapy. If eligible for the trial the patient is randomised to durvalumab or placebo.

While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.

Location

North Shore

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

State *

Postcode *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone

By submitting you acknowledge we will use the information you are providing to contact you about your enquiry. For more information about how we handle your personal information, please refer to the GenesisCare Privacy Policy.

MERMAID-2

Trial overview

Thank you for submitting.

An unexpected error has occurred.

How can we help?

GenesisCare

Website policies

Contact us

Media & Social